South America Bladder Cancer Therapeutics and Diagnostics Market

South America Bladder Cancer Therapeutics and Diagnostics Market Analysis

The South America Bladder Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 3% during the forecast period.

COVID-19 had a significant impact on the growth of the studied market. According to an article published in Elsevier in April 2021, it was observed that the average number of cancer diagnoses had dropped considerably in all Brazilian regions during the pandemic period, ranging from 24.3% in the North to 42.7% in the Northeast. Also, as per the same source, about a 66% reduction in the number of bladder diagnoses was reported in Brazil during the pandemic. However, the released restrictions and resumed diagnostics and treatment services have increased patient visits to the hospitals, which are expected to fuel the market growth over the forecast period.

Factors such as increasing awareness about bladder diseases, increasing healthcare expenditure, innovations in drug development, and availability of therapies are all expected to boost market growth over the forecast period.

The increasing prevalence of bladder cancer is the key factor driving the demand for effective therapeutics and novel diagnostics systems in the region. This is anticipated to fuel market growth. For instance, according to the 2023 statistics published by the Global Cancer Observatory, an estimated 4,176 new bladder cancer cases are expected to be diagnosed in Argentina in 2025, as compared to 3,785 cases during the pandemic (2020). In addition, as per the same source, about 2,403 and 1,823 new bladder cancer cases are expected to be diagnosed in Colombia and Chile, respectively, in 2025.

Additionally, the growing government and organizations' initiatives in launching awareness programs and campaigns regarding bladder cancer, its related therapeutics, and diagnostic methods are expected to increase the demand for treatment procedures. This is expected to augment the market growth in the region over the forecast period.

Furthermore, the rising company focus on adopting various strategies, such as product launches and mergers and acquisitions, increases the development and availability of novel products, which in turn also contributes to market growth. For instance, in August 2021, Photocure ASA, the Bladder Cancer Company, received the market authorization, for Hexvix, from Instituto de Salud Pública de in Chile.

Therefore, owing to the aforementioned factors, the studied market is anticipated to grow over the forecast period. However, the rise in the number of patent expirations and the asymptomatic nature of the disease is likely to impede the growth of the bladder cancer therapeutics and diagnostics market in South America over the forecast period.

South America Bladder Cancer Therapeutics and Diagnostics Market Trends

Cystoscopy Segment Expects to Register a Significant Growth Over the Forecast Period

Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is cost-effective. The segment is driven by rising in the adoption of cystoscopy, the rising prevalence of bladder cancer, and product launches by the key market players.

According to an article published in BMC, in February 2021, it has been observed that fluorescent cystoscopy using 5-aminolevulinic acid (ALA) or its hexyl ester, hexaminolevulinate improves tumor detection rate and recurrence-free survival (RFS) compared to white-light cystoscopy alone, in bladder cancer treatment. This is expected to increase the adoption of cystoscopy in the diagnosis of bladder cancer which in turn is anticipated to augment the segment's growth over the forecast period.

Therefore, owing to the aforementioned factors, such as the high adoption of cystoscopy, the studied market is expected to grow over the forecast period.

Brazil is Expected to Have the Significant Market Share Over the Forecast Period

Brazil is expected to witness a significant share in the bladder cancer therapeutics and diagnostics market over the forecast period. The factors propelling the market growth are the increasing burden of various types of bladder cancer and rising research studies.

According to an article published in the Journal of Epidemiology and Global Health, in September 2022, it has been observed that bladder cancer is the seventh most prevalent cancer in men and the sixteenth most prevalent cancer in women, in Brazil. Thus, the high burden of bladder cancer among the Brazillian population raises the demand for effective therapeutics and diagnostics devices which in turn is anticipated to fuel the market growth over the forecast period.

Additionally, the growing company activities in developing various diagnostic tests and products to effectively diagnose bladder cancer among the population is expected to fuel the market growth over the forecast period. For instance, in January 2023, Hoffmann-La Roche is conducting a Phase III clinical study to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with muscle-invasive bladder cancer who are ctDNA positive and are at high risk for recurrence following cystectomy, in Brazil. Also, in April 2021, Solve Biotechnology researchers, a Brazillian start-up company, are developing a rapid test to diagnose bladder cancer to reduce the number of invasive tests to which patients are submitted from the discovery of cancer to the end of treatment.

Therefore, owing to the above-mentioned factors such as the high burden of bladder cancer and increasing company activities, the studied market is expected to grow in Brazil over the forecast period.

South America Bladder Cancer Therapeutics and Diagnostics Industry Overview

The South American Bladder Cancer Market is moderately competitive and majorly dominated by a few players. With the rising technology and focus of various companies on drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share. Some of the key companies in the market are Pfizer Inc., Astra Zeneca PLC, Bristol Myers Squibb, Johnson and Johnson Inc., and Merck & Co. Inc., among others.

South America Bladder Cancer Therapeutics and Diagnostics Market Leaders

South America Bladder Cancer Therapeutics and Diagnostics Market News

• Feb 2023: Janssen Research & Development LLC is conducting a Phase III clinical study to evaluate the safety and efficacy of TAR-200 in combination with cetrelimab or TAR-200 alone versus intravesical bacillus Calmette-guérin (BCG) in participants with BCG-naïve high-risk non-muscle invasive bladder cancer, in Brazil.
• Feb 2023: AstraZeneca is conducting a Phase III clinical study to determine the safety and efficacy of a triplet combination of durvalumab, tremelimumab, and enfortumab vedotin to the current standard of care in patients with muscle-invasive bladder cancer.